\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
Insilico Medicine a Memorandum of Understanding with the Ministry of Investment of Saudi Arabia
Undersecretary of the Ministry Fahad Al-Naeem and founder and CEO of Insilico Medicine Alex Zhavoronkov
New York, Sept. 14, 2022 (GLOBE NEWSWIRE) — Saudi Arabia’s Ministry of Investment (MISA) and clinical-stage synthetic intelligence (AI)-focused drug discovery company Insilico Medicine have signed a Memorandum of Understanding for the progression of a powerful AI-powered biotechnology industry in the Kingdom. The agreement was signed at the Global AI Summit, held September 13-15 in Riyadh, which brought together more than two hundred speakers representing 90 countries to talk about the long-term of AI, adding Insilico Medicine founder and CEO Alex Zhavoronkov, PhD. Sara Althari, PhD, principal investigator and advisor to MISA, led the agreement.
MISA and Insilico Medicine will work on percentage projects that build on the functions of PharmaAI, Insilico’s AI-powered end-to-end drug discovery platform. Based on billions of knowledge points, the platform has 3 distinct but interconnected elements: new AI target discovery (PandaOmics), new AI drug design (Chemistry42), and AI clinical trial prediction (InClinico). Under the moU’s terms, Insilico will share its expertise and software platform with local biotech corporations to boost its drug studies and progression efforts. Through this partnership, the MoU also aims to stimulate the progress of new biotechnology corporations.
Insilico will also collaborate with Saudi companies on robotics-assisted drug design, clinical trial design and more productive practices. The company is launching a fully autonomous AI-powered robotics lab that will conduct experiments, capture data and further validate its findings and AI-engineered drugs later this fall. The company’s clinical trial prediction tool, InClinico, is designed to help researchers and companies plan trials with a higher statistical probability of success in Phase 2.
There will be more partnership opportunities in other spaces where Insilico’s AI platform has shown promise, adding support and launch projects similar to healthy longevity and supporting green chemistry initiatives, adding the progression of sustainable chemicals and crop cover solutions.
Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, said, “As someone who has to dedicate his life to prolonging productive and healthy longevity for everyone on the planet, I applaud Saudi Arabia’s new projects in this domain of maximum-impact studies. As a company, Saudi Arabia’s vision encourages us to grow its virtual economy and play a significant role in the long-term drug discovery using AI and robotics. We look to the future to work in combination to grow the region’s biotech sector and partner with established companies and emerging corporations, as well as educational and educational establishments to explore the full perspective of our end-to-end AI platform.
Over the past year, MISA signed memoranda with several pharmaceutical and generation corporations to expand its biotechnology business, adding Novartis, Janssen, AstraZeneca, GSK and Roche, as well as Amazon Saudi Arabia. Insilico Medicine, a company that bridges the gap between the pharmaceutical industry and generation, is the first AI-based drug discovery company to sign such an agreement in the region.
About Insilico Medicine
Insilico Medicine, a company dedicated to comprehensive synthetic intelligence (AI) at the clinical stage, connects biology, chemistry and clinical trial research with state-of-the-art AI formulas. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other fashionable device learning techniques to detect new targets and design new molecular structures with the desired properties. Insilico Medicine provides revolutionary responses to detect and expand cutting-edge drugs against cancer, fibrosis, immunity, diseases of the central nervous system. formula and diseases similar to aging.
More about www. insilico. com
For media inquiries, tap media@insilicomedicine. com
Attachments
Insilico Medicine a Memorandum of Understanding with the Ministry of Investment of Saudi Arabia
Undersecretary of the Ministry Fahad Al-Naeem and founder and CEO of Insilico Medicine Alex Zhavoronkov